Background/Aims: Breast cancer is a common cause of cancer mortality throughout the world. The cross-talk between cancer cells and interstitial cells exerts significant effects on neoplasia and tumor development and is modulated in part by chemokines. CXC is one of four chemokine families involved in mediating survival, angiogenesis, and immunosensitization by chemoattracting leukocytes, and it incentivizes tumor cell growth, invasion and metastasis in the tumor microenvironment. However, the differential expression profiles and prognostic values of these chemokines remains to be elucidated. Methods: In this study, we compared transcriptional CXC chemokines and survival data of patients with breast carcinoma (BC) using the ONCOMINE dataset, Kaplan-Meier Plotter, TCGA and cBioPortal. Results: We discovered increased mRNA levels for CXCL8/10/11/16/17, whereas mRNA expression of CXCL1/2/3/4/5/6/7/12/14 was lower in BC patients compared to non-tumor tissues. KaplanMeier plots revealed that high mRNA levels of CXCL1/2/3/4/5/6/7/12/14 correlate with relapse-free survival (RFS) in all types of BC patients. Conversely, high CXCL8/10/11 predicted worse RFS in BC patients. Significantly, high transcription levels of CXCL9/12/13/14 conferred an overall survival (OS) advantage in BC patients, while high levels of CXCL8 demonstrated shorter OS in all BC sufferers. Conclusions: Integrative bioinformatics analysis suggests that CXCL8/12/14 are potential suitable targets for precision therapy in BC patients compared to other CXC chemokines.
Identification of Potential Therapeutic

Introduction
Breast cancer (BC), the most prevalent cancer in the world among women, presents nearly 1.7 million new cases worldwide each year [1] . Due to remarkable advances made in diagnosis and therapy, the survival rates for BC patients have increased in regions with adequate medical research. In contrast, the efficacy of precision target therapies for BC remains stagnant due to multifaceted gene dysregulation and complex molecular mechanisms that involve multiple pathological and molecular subtypes. One of the classic molecular subtypes relies on expression of estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) to provide important clinical and predictive therapeutic information [2, 3] . Researchers and clinicians are increasingly regarding cancer as an imbalance between normal cells and the immune system. The cross-talk between cancer cells and immune cells is a pivotal part of cancer growth, metastasis, and treatment effects [4] . Hence, identifying novel biomarkers in the immune system for BC is urgent and required to achieve the goal of individualized treatment.
Chemokines are a family of low molecular weight, secreted signaling proteins well known for modulating immune cell trafficking and stromal cell development. Chemokines are classified into diverse groups according to their structural and behavioral characteristics. All chemokines are divided into four main classes based on their cysteine (C) residue sequence: the CXC chemokines, the CC chemokines, the C chemokines and CX3C chemokines, in which X represents any amino acid [5] . The nearly 50 chemokines identified in humans are divided into two differential functional groups: inflammatory chemokines and homeostatic chemokines. Inflammatory chemokines are usually induced by harmful stimulants, such as infections or cell damage, while homeostatic chemokines are constitutively expressed in normal immune network regulation. Aside from being known for mediating chemotaxis, most chemokines exhibit various additional functions related to cell proliferation and survival and to the stimulation or inhibition of angiogenesis.
Seventeen CXC chemokines have been described in humans. Interestingly, CXC chemokines can be further separated based on the presence or absence of an ELR (Glu, Leu, Arg) motif, which is situated before the first conserved cysteine residue. Almost all ELR + CXC chemokines are considered contributors to neutrophil aggregation and/or angiogenesis [6, 7] . In contrast, ELR -CXC chemokines attract lymphocytes, such as T cells, B cells, and natural killer (NK) cells [8, 9] . Although several studies have uncovered a general profile for CXC chemokines in BC, identifying suitable targets for precision therapy remains a challenge that urgently needs attention in this field. In the present study, we implemented a deep bioinformatics analysis of the clinicopathological and survival data as it relates to CXC chemokines in patients with BC based on several large public databases in order to illustrate their prognostic and potential therapeutic value in cancer treatment.
Materials and Methods
ONCOMINE data-mining analysis ONCOMINE (www.oncomine.org), an online web-based cancer database for RNA and DNA sequences, was used to facilitate data-mining the transcriptional expression of CXC chemokines in 20 types of cancer [10] . Transcriptional expression of CXCL chemokines in cancer samples were in compared with those in normal individuals using Student's t-test. Statistically significant values and fold change were demarcated as p<0.05 and 2, respectively. bcGenExMiner v4.0 Breast Cancer Gene-Expression Miner v4.0 (bcGenExMiner v4.0) is a statistical mining tool of 36 noted genomic datasets and three classical mining functions: expression, prognosis, and correlation [11, 12] . Expression data was updated in March 2016 and compares production of a particular gene with clinical Fig. 1 . Transcriptional levels of CXC chemokines in different types of cancers with the threshold of P-value≤1E-4, Fold Change≥2, and Gene Rank ≥Top 10%. This information was attained from ONCOMINE and indicates the numbers of datasets with statistically significant (p<0.05) mRNA high-expression (Red) or low-expression (Blue) of CXC chemokines (different types of cancer vs. corresponding normal tissue). Cell color was decided by the best gene rank percentile for the analyses within the cell, and the gene rank was analyzed by percentile of target genes in the top of all genes measured by each study. Figure 1 parameters such as age, ER, PR, HER2, and so on. The prognosis module calculates the prognostic value of target genes in BC and offers potential novel prognostic markers.
Kaplan-Meier Plotter
The prognostic value of CXC chemokine mRNA transcription level was measured using an online open database, the Kaplan-Meier Plotter (www.kmplot.com) [13] , which consists of gene expression profiles and survival information for 1, 809 BC patients. To evaluate the relapse-free survival (RFS) of patients with BC, individuals were separated into two groups based on median gene expression (high vs. low) and validated by K-M survival curves. The mean value of each CXC chemokine's multiple probes was determined to generate K-M survival curves, and the number-at-risk is displayed below the curves.
TCGA data and cBioPortal
The Cancer Genome Atlas (TCGA) contains gene expression data obtained by sequencing and has accurate clinical and pathological data on many cancers [14] . The cBioPortal (www. cbioportal.org) is an open-access data set for exploring multiple cancer genes. The BC dataset contains data from 1105 cases, with pathologic diagnosis chosen by cBioPortal for further analyses of CXC chemokines [15, 16] .
Results
Dysregulated expression of CXC chemokines in patients with BC
Sixteen CXC chemokines were identified using the ONCOMINE database, excluding CXCL15. As shown in Fig. 1 [23] .
Increased expression of CXCL2/12/13/14 and reduced expression of CXCL8 are correlated with preferable RFS or OS in BC patients
We separated all types of BC patients into one of two groups for chemokine expression (high vs low) based on median expression values for each chemokine across all samples. Fig. 1 presents transcription levels of CXC chemokines in different types of cancers with Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry the threshold of P-value≤1E-4, Fold Change≥2, and Gene Rank ≥Top 10%). This is true that IL-8 is not regulated in BC with this threshold. But IL-8 is overexpressed in BC with the threshold of P-value≤0.05, Fold Change≥2, and Gene Rank ≥Top 10%. When the chemokine expression of cancer is higher than that of adjacent non-tumor, we defined it as high expression and vice versa. The Kaplan-Meier curves for survival data indicated that increased CXCL1/2/3/4/5/6/7/12/14 mRNA levels and reduced CXCL8/10/11 mRNA levels are (Fig. 2) . Furthermore, BC patients with higher transcriptional levels of CXCL9/12/13/14 or lower mRNA levels of CXCL8 demonstrated better overall survival (OS) (Fig. 3) . To further investigate chemokine roles in Chen et al.: Therapeutic Targets Among CXCLs in TME the prognosis of BC, we also use bc-GenExMiner v4.0 to verify our findings. CXCL8 exerts the most significant negative effect on patient prognosis, and expression of CXCL2/12/13/14 was associated with better prognosis (Table 2) . (Fig. 4A) . Using bc-GenExMiner software, Welch's test was implemented to compare the aberrant expression of CXC chemokines between groups of patients based on different clinical pathological parameters. For age criterion (Fig.  5 A) , there was no significant difference between ≤ 51 year and > 51 year groups, except for CXCL2/13, which demonstrated reduced levels in the older group. BC patients with negative nodal status showed lower expression of CXCL2 than did positive nodal patients.
As shown in Fig. 5B , ER-positive or PR-positive patients tended to express low levels of CXCL2/8/13 and high levels of CXCL12/14 compared with ER-negative or PR-negative patients. ER-positive and PR-positive cancer cells depend on estrogen for their growth, so they can be treated with drugs to block estrogen effects (e.g., tamoxifen) and generally have a better prognosis [24] . Therefore, these results indicate that low expression of CXCL2/8/13 and high expression of CXCL12/14 may predict a better prognosis. In addition, CXCL2/8/13 expression was positively associated with HER2 status. Triple negative breast cancer (TNBC) is the most lethal type of BC, with a molecular signature including ER (-), PR (-) and HER2 (-). We found that CXCL2/8/13 mRNA expression was significantly increased in TNBC patients, while CXCL12/14 mRNA expression were significantly reduced in TNBC patients; the same pattern of change was observed in basal-like BC (Fig. 5) .
The Scarff, Bloom & Richardson grade (SBR) is an accepted prognostic factor that evaluates tubule formation, nuclear characteristics of pleiomorphism, and mitotic index. Patients with poorly differentiated tumors (grades II and III) have a decreased survival rate compared with those who have well-differentiated tumors (grade I). Based on SBR criterion (Fig. 4B,  C) , patients with high grade tumors (grades II and III) tended to express high levels of CXCL8 and low levels of CXCL2/12/14, consistent with our previous data. Apart from molecular subtypes, the Nottingham Prognostic Index (NPI) is also a useful prognostic model for BC patients. We found that lower expression of CXCL8 and higher expression of CXCL12/14 were correlated with the NPI. Combined with this information, multiple bioinformatics analyses identify CXCL8/12/14 as potential suitable therapeutic targets for BC patients. To visualize potential genes co-expressed with CXCL2/8/12/13, we constructed the gene network shown in Fig.  6 . The network is meant to identify potential interactions between CXCL2/8/12/13 and other key proteins. As shown in Fig. 5 , we found that CXCL2 was associated with other chemokines, including C X C L 1 / 3 / 4 / 6 / 1 1 / 1 2 and CCL28. CXCL8 was associated with IL15 and IL12. Of note, PIK3CA was related to both CXCL8 and CXCL12 expression. Erb-b2 receptor tyrosine kinase 2 (ERBB2), a key modulator of breast cancer [4] , indicating the crucial roles of CXC chemokine signaling pathways in multiple cancers and the efficacy of immunotherapies. However, the role of distinct CXC chemokines in the progression and metastasis of BC remain to be elucidated. To our knowledge, this is the first study to identify specific CXC chemokines with prognostic value and biological function in the tumor microenvironment using integrative bioinformatics (Table 4 
and 5).
Literature Review of Dysregulated CXC chemokines in breast cancer
A mini review of these CXC chemokines, their location, characteristics and known downstream targets is discussed below to suggest possible functional roles in breast tumorigenesis. , the first member of the CXC chemokine family, is considered an oncogene in BC. Cancer cells that overexpress CXCL1 attract CD11b+Gr1+ myeloid cells into the tumor stroma, stimulating secretion of S100A8/9, which enhances cancer cell survival and chemoresistance [25] . A pro-inflammatory interleukin, (IL)-17, significantly increases secretion of CXCL1 from breast carcinoma cells, suppressing function of myeloid-derived suppressor cells (MDSCs). MiR-200 was found to have both direct and indirect mechanisms of targeting CXCL1 to inhibit cancer angiogenesis [26] . In an experimental animal model, after co-injection of CXCL1 with human adipose-derived mesenchymal stem cells (hADSCs), hADSCs promoted residual BC proliferation and metastasis via the PI3K/AKT/SOX2 axis [27] . CXCL2 shares 90% amino acid homology with CXCL1. As a pro-inflammatory and pro-oncogenic factor, BC patients with high CXCL2 mRNA levels have a prognostic disadvantage. Kronski et al. has shown that miR-181b modulates the expression of CXCL1 and CXCL2, inhibiting breast cancer growth and invasion [28] . Constitutive CXCL3 activation has been reported in some human cancers with a poor prognosis as a potential therapeutic target [29] . Bone-marrow-derived mesenchymal stem cells (MSCs) may facilitate breast cancer progression by releasing CXCL3 with transforming growth factor-α (TGFα) [30] . As few studies have focused on CXCL3, the underlining function of CXCL3 still needs additional research. CXCL4, known as platelet factor 4 (PF4), is released from activated platelets and binds with high affinity to heparin. In a mouse model, CXCL4 was shown to reduce breast cancer growth and proliferation of endothelial cells in vivo [31] . Of note, CXCL4 is produced by Ly6G+CD11b+ myeloid cells in the pre-metastatic stage, but production is lowered in the metastatic stage [32] . Controversially, Pucci et al. reported that CXCL4 induces platelet accumulation to promote lung adenocarcinoma in a demonstration of tumor-host communication [33] . There is little information on CXCL5 in BC. In the bone metastasis microenvironment, breast tumor associated osteoblasts (TAOs) secrete CXCL5 to mediate cancer development via the ERK/MSK1/Elk-1/Snail signaling pathway [34] . As mentioned above, (IL)-17 significantly increases secretion of CXCL1 and CXCL5 from breast carcinoma cells, suppressing the function of MDSCs [35] . As its former name granulocyte protein 2 (GCP-2) indicates, CXCL6 is a chemoattractant for neutrophils. Neutrophils within tumor stroma facilitate cancer invasion and metastasis. Due to lack of original research articles concerning the role of CXCL6 in BC, we speculate that CXCL6 may serve as a protooncogene in the tumor microenvironment [36] . CXCL7 is an isoform of pro-platelet basic protein (PPBP), which is released from activated platelets. In cell-to-cell communication between breast cancer stem cells (CSCs) and MSCs, CSCs produce IL6 to attract MSCs, which produce CXCL7 in response to IL6. In turn, CXCL7 induces the secretion of many cytokines from mesenchymal cells, including IL6, IL8, CXCL6 and CXCL5 [37] .
CXCL8, previously called IL8, is a cytokine involved in cell-cell communication between cancer cells and neutrophils in the breast carcinoma microenvironment. Some transcription factors orchestrate key functions for increasing levels of CXCL8. The nuclear factor of activated T cells (NFAT) stimulates expression of CXCL8 by binding to its promoter and soliciting neutrophils in vitro and in vivo [38] . Tumor necrosis factor α (TNFα)-activated mesenchymal stromal cells accelerate breast tumor progression via neutrophil aggregation [39] . Considering hormone receptor criteria, CXCL8 deficiency inhibits hormone-resistant cell growth and invasion, in part attenuating the effect of Forkhead box protein A1 (FOXA1) function in ER+ breast cancer [40] .
CXCL9/10/11/12/13/14 as tumor suppressors CXCL9, known as monokine induced by gamma interferon (MIG), is a T-cell chemoattractant that is usually induced by IFN-γ. We found that high transcription levels of CXCL9 conferred an overall survival advantage in all BC patients, consistent with previous findings. Some researchers have already discovered that IFN-γ exhibits a powerful influence on the secretion and expression of CXCL9 and CXCL10 [41, 42] . The GeparSixto trial revealed that as an immune-activating factor, CXCL9 shows a positive correlation with PD-1 [43] . Brackett et al., found that the toll-like receptor-5 agonist entolimod quickly activates an Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry innate antitumor response predominantly by attracting CXCR3+ NK cells using CXCL9 and CXCL10 [44] . Our study confirms that high transcription levels of CXCL9 confer an overall survival advantage in all BC patients and is a promising prognostic factor. Intratumoral hypoxia triggers metastasis by activation and release of hypoxia-inducible factors (HIFs). Under hypoxic conditions, breast cancer cells increase HIF activity via MSC and cancer cell communication. Additionally, co-existence of two kinds of cells induce expression of the chemokine CXCL10 in MSCs to support metastasis to lymph nodes and lungs [45, 46] . However, in recent studies, the idea of CXCL10 as a potent chemoattractant has received more attention. For example, type I IFNs trigger autocrine and paracrine circuits that accelerate the release of CXCL10 [47] . Mammary epithelial cells (MECs) create elevated expression of CXCL10 via type I IFNs as well [48] . Notably, combinatorial therapy with celecoxib and PD-1 mAb increases expression of CXCL9 and CXCL10 [49] .
It has been demonstrated that CXCL11 has similar chemotactic functions as CXCL9 and is located near the CXCL9 gene on human chromosome 4. Unfortunately, not much research has focused on CXCL11 in BC. The stimulation of IFN genes (STING) triggers macrophage production of TNFα and high expression levels of the T cell-recruiting chemokines CXCL10 and CXCL11 [50] .
Many different interstitial cell subsets are recruited into the tumor microenvironment via cell-to-cell communication between CXCL12 and its receptor CXCR4. However, CXCL12 and CXCR4 have disparate functions on breast tumorigenesis and outcomes depending on the specific immune cell type and conditions present [51] . Yu et al. demonstrated that transforming growth factor β (TGFβ) impairs MSCs ability to secrete CXCL12 and therefore promotes breast cancer metastasis [52] , consistent with our findings. Recently, Xia et al. found that B cells directly kill BC cells using CXCR4/CXCL12 pathways, indicating that CXCL12 functions as a tumor suppressor [53] . Bioinformatics analysis also suggested that CXCL12 is an independent prognostic indicator. Contradictorily, CXCL12 is robustly increased in perivascular sites after chemotherapy, where it also carries out chemotaxis for tumorassociated macrophages [54] .
CXCL13, known as B lymphocyte chemoattractant (BCL), was frequently found in the interaction between cancer cells and B cells [55] . RORγt+ group 3 innate lymphoid also stimulated the expression of CXCL13 by stromal cells in the microenvironment and largely contributed to lymph node metastases [56] . Additionally, p53 deficiency was shown to activate CXCR5 expression in response to CXCL13 [57] . Nonetheless, Stoll et al. stated that expression of CXCL13 cardinally reflects the levels of effector T cells within the tumor bed, suggesting that CXCL13 might have a suppressive role in tumor progression [58] .
Previously, CXCL14's role as a negative modulator of cancer growth and metastasis seemed well established [59] ; however, a recent investigation revealed that CXCL14 might actually assist in tumor development and progression. Epithelial CXCL14 levels are markedly correlated with ER + tumors and lower proliferation status. Interestingly, total (epithelial and stromal) CXCL14 level is dramatically associated with decreased RFS [60] . Cross-talk between cancer cells and cancer-associated fibroblasts (CAFs) is also relevant to cancer research. CXCL14 is a potent executor of CAFs' pro-tumorigenic functions. Of note, nitric oxide synthase (NOS1) has increased expression in CAF and, with CXCL14, stimulates CAFs. NOS1 can speed up tumor growth with the assistance of CXCL14-expressing CAFs [61] . Furthermore, lower miR-29b expression in CAFs can accelerate metastasis by activating the p38-STAT1 pathway in breast cancer cells and up-regulating CXCL14 and CCL11 in CAFs. Additionally, STAT1 increases expression of CXCL14 and CCL11 at the transcription level [62] . Kaplan-Meier curves revealed that high CXCL14 mRNA levels were correlated with favorable relapse-free survival (RFS) in all types of BC patients, and high transcription levels of CXCL14 conferred an overall survival (OS) advantage in all BC patients. These results suggest that CXCL14 is a potential target for precision therapy in BC patients.
BC cells secrete CXCL16 that binds to CXCR6 on MSCs. In turn, MSCs secrete CXCL10 that binds to CXCR3 on cancer cells. This feedback loop drives accumulation of tumor-associated macrophages (TAMs) and MDSCs [46] . CXCR6 was found not only in stromal cells but was also [64] . CXCL17 is also called VEGF co-regulated chemokine 1 (VCC-1) and dendritic cell-and monocyte-attracting chemokine-like protein (DMC). Cancer cell-derived CXCL17 recruits MDSCs to tumor sites and facilitates tumorigenesis and angiogenesis [65] .
Comparison of mini review of CXC chemokines with our results
Overall, we illustrated that cross-talk between breast cancer cells and immune cells is mediated by CXC chemokines in the tumor microenvironment ( Fig. 7 and Table 3 ). Although CXC chemokines are reported to affect OS and RFS in BC patients, the dominant regulatory factors and underlying mechanism are still unclear. The exact mechanism of CXC chemokine involvement in BC patient prognosis requires more investigation.
The above mini-review indicates that CXCL1/2/3/4/5/6/7 may function as protooncogenes in the tumor microenvironment, which contradicts our findings. The CXC chemokine expression profiles in the dataset are primarily from RNA sequences. These disparities may stem from differences between clinical samples and experimental conditions used in each study. Of note, in this study, we report that CXCL8 mRNA level is significantly overexpressed in breast cancer and increased in higher SBR grades, which predict rapidgrowing, metastatic tumors. This result is consistent with previous reports. Furthermore, high levels of CXCL8 indicated shorter OS in all BC patients, representing a potential therapeutic target.
In the current study, we systemically analyzed transcriptional expression and prognostic values for all CXC chemokines in BC, supplying a more profound understanding of the complicated dysregulation in the molecular biology of BC. Integrative bioinformatics analysis suggests that CXCL8/12/14, compared to other CXC chemokines, are potential suitable targets for precision treatment in BC patients. However, other multiple clinical trials are required to validate the diagnostic potentials of these CXC chemokines. Additionally, more in-depth experiments, such as single cell sequencing, are necessary to explore the underlying mechanism of cross-talk between cancer cells and stromal cells in BC. 
